Top Page
Evogene
(NASDAQ:EVGN)
Evogene (EVGN) vs. SPDR S&P 500 ETF (SPY)
Evogene Business Overview & Revenue Model
Evogene Earnings Call Summary
Evogene Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.85M | 8.51M | 5.64M | 1.68M | 930.00K |
| Gross Profit | 795.00K | 3.39M | 1.40M | -1.77M | -2.07M |
| EBITDA | -12.85M | -15.38M | -23.20M | -26.93M | -27.80M |
| Net Income | -8.48M | -16.48M | -23.88M | -26.64M | -27.79M |
Balance Sheet | |||||
| Total Assets | 20.05M | 39.86M | 51.10M | 56.13M | 76.30M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 15.31M | 31.06M | 35.35M | 53.87M |
| Total Debt | 2.20M | 12.87M | 11.51M | 11.93M | 2.67M |
| Total Liabilities | 5.00M | 25.03M | 22.42M | 21.34M | 12.88M |
| Stockholders Equity | -82.00K | -1.45M | 12.05M | 27.93M | 53.65M |
Cash Flow | |||||
| Free Cash Flow | -13.64M | -20.33M | -22.36M | -24.85M | -25.56M |
| Operating Cash Flow | -13.50M | -19.70M | -21.58M | -23.68M | -24.84M |
| Investing Cash Flow | 17.74M | 9.62M | -4.54M | 13.27M | -20.44M |
| Financing Cash Flow | -6.60M | 4.66M | 18.15M | 9.34M | 30.28M |
Evogene Technical Analysis
Evogene Risk Analysis
Evogene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $82.56M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
49 Neutral | $91.88M | -0.50 | 337.03% | ― | -98.25% | 63.05% | |
49 Neutral | $8.73M | -3.61 | -154.50% | ― | ― | 54.25% | |
44 Neutral | $6.90M | -0.45 | 553.15% | ― | -29.78% | 88.96% | |
41 Neutral | $8.72M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
39 Underperform | $414.62K | ― | -1302.82% | ― | ― | 99.09% |
Evogene Corporate Events
On March 5, 2026, Evogene reported its fourth-quarter and full-year 2025 results, highlighting a strategic overhaul that consolidated the business around its ChemPass AI engine for small-molecule discovery in pharma and agriculture and exited non-core activities. The company integrated AgPlenus into its core operations, curtailed Casterra’s Kenyan seed business, and saw subsidiaries Lavie Bio and Biomica effectively wound down following the 2025 sale of Lavie Bio’s operations to ICL and the early-2026 out-licensing of Biomica’s lead oncology asset, with both units expected to return excess cash to shareholders.
The restructuring produced a sharp reduction in operating expenses to about $13.8 million in 2025 from $22.0 million in 2024, even as revenue fell to $3.9 million from $5.6 million due mainly to lower AgPlenus and Casterra contributions and a one-time 2024 payment. Evogene ended 2025 with roughly $13.0 million in cash and supplemented liquidity in February 2026 via a $3.4 million warrant inducement deal, while absorbing a $2.2 million Casterra inventory impairment that drove cost of revenues higher, signaling a leaner but more tightly focused platform business for investors and partners.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
On February 25, 2026, Evogene released a CEO letter to shareholders outlining a strategic transformation undertaken in 2025 to sharpen its focus and capital allocation. The company consolidated technology development around its ChemPass AI™ platform and narrowed operations to two core markets, human health and agriculture, restructuring the organization and divesting non-core assets to become more agile and capital-efficient.
The letter highlighted ChemPass AI™’s ability to generate original small molecules from a 38-billion-compound universe while meeting complex multi-parameter requirements, underpinning collaborations such as an ongoing second project with Google Cloud. Evogene reported progress in multiple partnered drug discovery programs in human health and continued growth in agricultural collaborations through its AgPlenus subsidiary with partners including Bayer and Corteva, while retaining selective exposure to remaining assets like Casterra.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
On February 10, 2026, Evogene entered into a warrant inducement agreement with an existing institutional investor, leading to the immediate cash exercise of August 2024 Series A and Series B warrants for 3,384,616 ordinary shares at a reduced price of $1.00 per share. The transaction is expected to provide approximately $3.4 million in gross proceeds, earmarked for working capital and general corporate purposes, and is slated to close around February 11, 2026, subject to customary conditions.
In return for the early exercise, Evogene will issue 5,076,924 new unregistered Series A-1 and Series B-1 warrants, split evenly, with an exercise price of $1.25 per share and terms of five years and 18 months, respectively. The company has engaged A.G.P./Alliance Global Partners as sole financial advisor, committed to register the resale of shares underlying the new warrants, and agreed to short-term restrictions on issuing additional equity or variable-rate financings, a structure that boosts near-term liquidity while adding potential future dilution for shareholders.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
On February 4, 2026, Evogene announced that its microbiome-focused subsidiary Biomica has signed an exclusive worldwide licensing deal with Shanghai-based clinical-stage biotech firm Lishan Biopharmaceuticals for BMC128, a first-in-class microbiome-based therapeutic being developed for renal cell carcinoma and non-small cell lung cancer. BMC128, a live bacterial consortium of four gut strains designed to boost anti-tumor immune activity and enhance responses to immunotherapy, is currently completing a Phase 1 trial with promising safety, tolerability and early signs of efficacy, and under the agreement Lishan will take over global clinical development, manufacturing and commercialization while Biomica becomes eligible for development and sales-based milestone payments and royalties, positioning Evogene and its subsidiary to participate financially in the program’s future progress and reinforcing their standing in the emerging field of microbiome oncology therapeutics.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
On January 15, 2026, Israel-based Evogene Ltd. reported a senior management change, announcing that Chief Financial Officer Yaron Eldad has submitted his resignation for personal reasons, effective March 31, 2026, with the company clarifying that his departure does not stem from any disagreement over its operations, policies or practices. VP Finance Polina Ravzin, who has held that position since 2022 and previously served in finance roles at DSIT Solutions Ltd. and Acorn Energy Inc., will retain her current role while also assuming the responsibilities of CFO, signaling continuity in Evogene’s financial leadership structure during the transition.
The most recent analyst rating on (EVGN) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
On December 30, 2025, Israel-based Evogene Ltd. announced that it has appointed Dr. Olga Nissan as its Vice President of Business Development, effective January 1, 2026, marking a key addition to its leadership team. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceuticals, diagnostics and agri-biotechnology, with previous roles including CEO and Co-Founder of Protica Bio and positions at EcoPhage, BiomX and Teva Pharmaceutical Industries; the company’s leadership expects her expertise in AI-enabled drug discovery, strategic partnerships and company-building to support the scaling of Evogene’s ChemPass AI-driven small-molecule discovery and optimization activities and to strengthen collaborations with industry partners.
The most recent analyst rating on (EVGN) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.